2026-2034年全球肺病治療市場規模、佔有率、趨勢和成長分析報告

預計到 2034 年，肺部疾病治療市場規模將從 2025 年的 933.4 億美元達到 1,323.9 億美元，並預計從 2026 年到 2034 年將以 3.96% 的複合年成長率成長。

受氣喘、慢性阻塞性肺病（COPD）、肺纖維化和肺部感染疾病等呼吸系統疾病日益普遍的推動，全球肺部疾病治療市場正經歷穩定成長。空氣污染加劇、吸菸習慣、職業危害以及人口老化是導致患者數量顯著增加的重要因素。診斷率的提高和早期治療意識的增強也促進了已開發國家和新興市場的發展。

藥物創新在推動這一市場發展中發揮著至關重要的作用。生物目標、聯合治療和先進吸入給藥系統的研發正在改善治療效果。各國政府和醫療機構加大對呼吸系統健康計畫的投入，進一步刺激了對有效療法的需求。此外，呼吸道感染疾病和病毒感染後併發症的影響也促進了肺部相關藥物的研發。

展望未來，精準醫療方法和根據基因資訊及疾病特異性因素量身定做的個人化療法可望惠及市場。發展中地區醫療保健覆蓋範圍的擴大以及新藥候選藥物臨床試驗的增加將進一步加速市場成長。與數位醫療、遠端監測和改進的藥物輸送系統的融合，有望重塑全球肺部疾病管理的未來。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球肺部疾病治療市場：依疾病類型分類

• 市場分析、洞察與預測
• 氣喘
• 慢性阻塞性肺病（COPD）
• 肺癌
• 其他肺部疾病

第5章 全球肺部疾病治療市場：依藥物類別分類

• 市場分析、洞察與預測
• 皮質類固醇
• 支氣管擴張劑
• 祛痰藥
• 抗生素
• 其他

第6章 全球肺病治療市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第7章 全球肺部疾病治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 亞太其他地區
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • GSK
  • AstraZeneca
  • Boehringer Ingelheim
  • Novartis
  • Mylan
  • Vertex Pharmaceuticals
  • F. Hoffman La Roche
  • Teva Pharmaceuticals
  • Cipla
  • Fibrogen
  • Liminal Biosciences
  • PharmAkea Therapeutics
  • IQVIA
  • Sanofi
  • Bayer

The Lung Disease Therapeutics Market size is expected to reach USD 132.39 Billion in 2034 from USD 93.34 Billion (2025) growing at a CAGR of 3.96% during 2026-2034.

The global lung disease therapeutics market is witnessing steady growth driven by the rising prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and lung infections. Increasing air pollution levels, smoking habits, occupational hazards, and aging populations are significantly contributing to the expanding patient pool. Improved diagnosis rates and growing awareness about early treatment are also supporting market expansion across developed and emerging economies.

Pharmaceutical innovation plays a key role in driving this market forward. The development of targeted biologics, combination therapies, and advanced inhalation delivery systems has enhanced treatment outcomes. Governments and healthcare organizations are investing in respiratory health programs, further boosting demand for effective therapeutics. Additionally, the impact of respiratory infections and post-viral complications has intensified research and funding in lung-related drug development.

Looking ahead, the market is expected to benefit from precision medicine approaches and personalized therapies tailored to genetic and disease-specific factors. Expanding healthcare access in developing regions and increasing clinical trials for novel drug candidates will further accelerate growth. Digital health integration, remote monitoring, and improved drug delivery systems are likely to shape the future of lung disease management globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Disease Type

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Lung Cancer
• Other Lung Diseases

By Drug Class

• Corticosteroids
• Bronchodilator Medications
• Mucolytics
• Antimicrobial Medications
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• GSK, AstraZeneca, Boehringer Ingelheim, Novartis, Mylan, Vertex Pharmaceuticals, F Hoffman La Roche, Teva Pharmaceuticals, Cipla, Fibrogen, Liminal Biosciences, PharmAkea Therapeutics, IQVIA, Sanofi, Bayer
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL LUNG DISEASE THERAPEUTICS MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Disease Type
• 4.2. Asthma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Chronic Obstructive Pulmonary Disease (COPD) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Other Lung Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL LUNG DISEASE THERAPEUTICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Bronchodilator Medications Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Mucolytics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Antimicrobial Medications Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL LUNG DISEASE THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL LUNG DISEASE THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Disease Type
  • 7.2.2 By Drug Class
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Disease Type
  • 7.3.2 By Drug Class
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Disease Type
  • 7.4.2 By Drug Class
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Disease Type
  • 7.5.2 By Drug Class
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Disease Type
  • 7.6.2 By Drug Class
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL LUNG DISEASE THERAPEUTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 GSK
  • 9.2.2 AstraZeneca
  • 9.2.3 Boehringer Ingelheim
  • 9.2.4 Novartis
  • 9.2.5 Mylan
  • 9.2.6 Vertex Pharmaceuticals
  • 9.2.7 F. Hoffman La Roche
  • 9.2.8 Teva Pharmaceuticals
  • 9.2.9 Cipla
  • 9.2.10 Fibrogen
  • 9.2.11 Liminal Biosciences
  • 9.2.12 PharmAkea Therapeutics
  • 9.2.13 IQVIA
  • 9.2.14 Sanofi
  • 9.2.15 Bayer